BioCentury | Apr 23, 2020
Product Development

Roche reveals trial failures

Along with its 1Q20 earnings, Roche disclosed negative readouts in three clinical trials. Following a futility analysis, Roche (SIX:ROG; OTCQX:RHHBY) stopped the Phase III V1aduct trial of V1a receptor antagonist balovaptan (RG7314) to treat adults...
BioCentury | May 23, 2017

Misalignment in autism

FDA ’s Patient-Focused Drug Development meeting on autism revealed two different stakeholder groups with rather different priorities. Individuals with autism who were able to speak on their own behalf said their primary concerns are not...
BC Innovations | Nov 14, 2013
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Excessive sleepiness Vasopressin 1a (V1a) receptor; V1b receptor Mouse studies suggest antagonizing the V1a or V1b receptors could be useful for treating sleep disturbance caused...
BioCentury | Nov 11, 2013

New York translation

Now headquartered at the newly opened Translational Clinical Research Center in New York, Roche 's Pharma Research & Early Development organization has undergone another retooling intended to increase its efficiency and productivity. The center will...
BC Week In Review | Nov 4, 2013
Clinical News

RG7314: Phase II started

Roche disclosed in its 3Q13 earnings that it began a double-blind, placebo-controlled Phase II trial to evaluate daily oral RG7314 in about 150 patients with ASD. In stage I, patients will receive 1.5 mg RG7314...
BC Week In Review | Feb 4, 2013
Clinical News

RG7314: Phase I started

Roche said in its 4Q12 earnings that it began a Phase I trial to evaluate multiple doses of RG7314 in combination with a single dose of risperidone in up to 24 healthy volunteers. Roche (SIX:ROG;...
BioCentury | Oct 8, 2012
Product Development

Contrarian thinking

While many pharma companies are exiting or externalizing neurology R&D, a few have decided to double down, seeing the glimmer of a new understanding of CNS diseases where others see biological black boxes leading to...
BioCentury | Jun 25, 2012

Fragile X connection

Last week's deal between Seaside Therapeutics Inc. and Roche has a slew of moving parts, with a different driver for each party. The key for the biotech was granting Roche an option to its lead...
BC Innovations | Apr 19, 2012

Building tools against autism

As information about the genetic underpinnings of autism spectrum disorder has proliferated, so too have questions about how subtle changes in a seemingly diverse set of genes can lead to similar clinical pathology. This month,...
Items per page:
1 - 9 of 9